Related Experiment Videos
[High-dose intravitreal ganciclovir in CMV retinitis]
I Cochereau1, M C Diraison, H Mousalatti
1Service d'Ophtalmologie, Hôpital Bichat, Paris. oph.sec@bch.ap-hop-paris.fr
Journal Francais D'Ophtalmologie
|March 8, 2000
Summary
High-dose intravitreous ganciclovir (2000microg) effectively maintained remission for cytomegalovirus (CMV) retinitis in AIDS patients with a low relapse rate and no observed ocular toxicity.
Area of Science:
- Ophthalmology
- Infectious Diseases
- Virology
Context:
- Cytomegalovirus (CMV) retinitis is a significant opportunistic infection in patients with Acquired Immunodeficiency Syndrome (AIDS).
- Maintenance therapy is crucial to prevent relapse and preserve vision in affected individuals.
- Previous treatment regimens utilized lower doses of intravitreous ganciclovir.
Purpose:
- To evaluate the efficacy and safety of a high-dose (2000microg) intravitreous ganciclovir regimen for CMV retinitis maintenance therapy in AIDS patients.
- To compare the outcomes with historical lower-dose treatments.
Summary:
- A prospective, single-center study included 24 eyes from 15 AIDS patients receiving weekly 2000microg intravitreous ganciclovir injections.
- Clinical examinations and photographic documentation were used for evaluation.
- The study followed patients for 44 weeks, assessing relapse rates and ocular toxicity.
Impact:
- High-dose intravitreous ganciclovir demonstrated a prolonged remission rate of CMV retinitis, with only a 5% relapse rate at 44 weeks.
- The treatment was well-tolerated, with no reported ocular toxicity after 24 weeks of follow-up.
- This supports the recommendation of using the 2000microg dosage over the conventional 400microg dose for enhanced therapeutic outcomes.